Optimising survival in malignant mesothelioma

Area of Science:

• Oncology
• Pulmonology
• Pathology

Background:

• Malignant pleural mesothelioma incidence is increasing worldwide.
• Early detection and diagnosis methods, including tumor markers and genomic analysis, are under investigation.
• Accurate histological confirmation by expert pathologists is crucial to differentiate from other tumors.

Purpose of the Study:

• To review the current status of malignant pleural mesothelioma diagnosis and treatment.
• To highlight the challenges and ongoing research in early detection.
• To emphasize the importance of established diagnostic and therapeutic protocols.

Main Methods:

• Review of current literature and clinical guidelines for malignant pleural mesothelioma.
• Discussion of diagnostic modalities, including histological confirmation and staging systems.
• Summary of standard treatment protocols based on clinical trial evidence.

Main Results:

• Survival rates for malignant pleural mesothelioma have shown recent improvement.
• The International Mesothelioma Interest Group (IMIG) staging system is preferred but requires surgical staging.
• Cisplatin and pemetrexed combination therapy is the current standard treatment.

Conclusions:

• Early detection of malignant pleural mesothelioma remains a significant challenge.
• Accurate pathological diagnosis and staging are critical for effective management.
• Prompt initiation of standard chemotherapy (cisplatin and pemetrexed) is recommended for improved outcomes.